Efficacy of a fixed-dose combination of 40 mg penbutolol with 6 mg piretanide in the treatment of mild to moderate hypertension: a double-blind study against placebo

1987 ◽  
Vol 10 (6) ◽  
pp. 397-406 ◽  
Author(s):  
J. Yasky ◽  
M. Verho ◽  
B. Rangoonwala
Keyword(s):  
Moderate Hypertension ◽  
Blind Study ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Double Blind Study ◽  
Double Blind ◽  
Dose Combination

scholarly journals Fixed Dose Combination of Magaldrate Plus Domperidone Is More Effective than Domperidone Alone in the Treatment of Patients with Gastroesophageal Reflux Symptoms: A Randomized Double-Blind Study

2014 ◽  
Vol 05 (02) ◽  
pp. 216-223 ◽  
Author(s):  
Shendel Nyx Rodríguez-Sánchez ◽  
Héctor Isaac Rocha-González ◽  
Cecilia Fernández del Valle-Laisequilla ◽  
Juan Rodríguez-Silverio ◽  
Francisco Javier Flores-Murrieta ◽  
...  
Keyword(s):  
Gastroesophageal Reflux ◽  
Blind Study ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Double Blind Study ◽  
Double Blind ◽  
Reflux Symptoms ◽  
Dose Combination

scholarly journals Combine therapy as a modern approach to treatment of allergic rhinitis

2021 ◽  
Vol 93 (8) ◽  
pp. 986-990
Author(s):  
Alexander V. Emelyanov
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Allergic Rhinitis ◽  
Suboptimal Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Double Blind ◽  
Modern Approach ◽  
Dose Combination

Allergic rhinitis (AR) is one the most common allergic diseases affecting from 10 to 40% of the population in different countries, including Russia. AR is a risk factor of bronchial asthma, other upper airway disease and may decrease patient quality of life, their productivity, increase probability of occupational traumatism, depression and anxiety. AR also presents a substantial economic burden. The rationale to use fixed dose combination of intranasal steroids and topical H1 antihistamines includes suboptimal control of symptoms by monotherapy, its complementary pharmacologic activity and the results of clinical trials. This review focused on fixed dose combination of intranasal mometasone furoate and olopataine. Double blind placebo-controlled and open clinical trials have confirmed that this combination decreased severity of nasal and ocular symptoms of seasonal and perennial AR, improved patient quality of life and had a good tolerability. Its efficacy was higher than those of monotherapy. Fast onset of action and sustainable effect on symptoms (during 1 yr) may improve adherence patients to the treatment and control of symptoms of AR.

Sign in / Sign up

Export Citation Format

Share Document